PAR 6.67% 24.0¢ paradigm biopharmaceuticals limited..

Ann: PAR Reports Phase 3 Clinical Trial Update, page-17

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,216 Posts.
    lightbulb Created with Sketch. 1375
    I asked the same question a year ago and someone mentioned that Simon said 2mg/kg was still on the table, although there's been nothing in writing, so I would go by the official messaging and assume that it's only one of the doses from stage 1. I'm also not sure if we get a readout for stage 1 002 since that would involve unblinding the study. I'm also not sure how the DMC are evaluating overwhelming/underwhelming efficacy, so I can't read too much into us being allowed to continue the trial without modification. However, if we do get a readout and all doses are underwhelming PAR should be able to reapply to the FDA and request to dose at 2mg/kg.

    On another note, today's announcement indicates that we've enrolled 468 patients into PARA 002 in ~ 18 months. So if all goes well, imagine where PAR will be in the next 18 months.

    My views, dyor
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
24.0¢
Change
0.015(6.67%)
Mkt cap ! $83.98M
Open High Low Value Volume
22.5¢ 24.0¢ 22.5¢ $173.6K 743.6K

Buyers (Bids)

No. Vol. Price($)
8 99346 22.5¢
 

Sellers (Offers)

Price($) Vol. No.
24.0¢ 131244 5
View Market Depth
Last trade - 16.10pm 13/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.